Monopar Therapeutics Inc. (MNPR) fundamentals score
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company developing an innovative treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 3.7 out of 10, Weak long-term fundamentals
- Growth: 3.5/10
- Profitability: 1.0/10
- Financial health: 8.0/10
- Earnings quality: 5.1/10
- Valuation: 1.5/10
Scores are calculated from Monopar Therapeutics Inc.’s SEC filings, using the 12 months through 2025-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10